Sofosbuvir/Velpatasvir Concentrations in the Breastmilk of Postpartum Women with Opioid Use Disorder Receiving Treatment for Hepatitis C Virus: a pharmacokinetic study.

In this breastmilk pharmacokinetic study of women undergoing hepatitis C virus treatment with sofosbuvir/velpatasvir, sofosbuvir, GS-331007 (sofosbuvir metabolite), and velpatasvir concentrations in breast milk were 13%, 1.2%, and 41% of maternal plasma concentrations, respectively. The estimated infant daily dose from breastmilk was <1% of the weight-adjusted dose for children.

Intracellular Islatravir-Triphosphate in Dried Blood Spots and Peripheral Blood Mononuclear Cells from Pig-Tailed Macaques.

The purpose of this study was to evaluate the relationship between intracellular islatravir-triphosphate (ISL-TP) in paired peripheral blood mononuclear cells (PBMCs) and dried blood spots (DBS). Three pig-tailed macaques (PMs) were dosed with a single intravaginal extended-release ISL-etonogestrel film for a period of 31 days. After extraction and quantification, repeated measures correlation (r) was assessed between log-transformed DBS and PBMC ISL-TP concentrations.

PFKFB3 Inhibits Fructose Metabolism in Pulmonary Microvascular Endothelial Cells.

Pulmonary microvascular endothelial cells contribute to the integrity of the lung gas exchange interface, and they are highly glycolytic. Although glucose and fructose represent discrete substrates available for glycolysis, pulmonary microvascular endothelial cells prefer glucose over fructose, and the mechanisms involved in this selection are unknown. 6-Phosphofructo-2-kinase/fructose-2, 6-bisphosphatase 3 (PFKFB3) is an important glycolytic enzyme that drives glycolytic flux against negative feedback and links glycolytic and fructolytic pathways.